Medulloblastoma is a cancer in the back of the brain. In this study, researchers are testing if adding sodium thiosulfate (STS) can lessen hearing loss caused by the cancer treatment. Treatment usually involves surgery, radiation (high-energy rays to kill cancer cells), and chemotherapy with drugs like cisplatin (which can cause hearing loss). For average-risk patients, STS is added to see if it helps with hearing. For low-risk patients, the study checks if using less radiation is still effective but with fewer side effects.

Key Points:

• The study lasts up to 10 years, with regular check-ups.
• Participation includes regular MRIs and optional blood tests.
• Potential risks include standard treatment side effects, but STS may help reduce hearing loss.

Enrollment is open to patients aged 4-21. Participants cannot have received prior radiation or chemotherapy, and must be free of metastatic disease (cancer spread) and pregnancy. The study aims to improve long-term outcomes for children with medulloblastoma by reducing the side effects of treatment.